Wall Street expects TransMedics Group to report Q3 2026 revenue of $178.05 million and EPS of $0.27, with the stock currently priced at $68.44 against an average analyst target of $102.20.
The key story for this report is the company's adjusted operating margin, as analysts look for signs of stabilization following heavy spending on aviation infrastructure and the kidney transplant program.
While the OCS Liver and Heart segments continue to drive strong top-line growth of nearly 24% year-over-year, profitability is being temporarily weighed down by the integration of the PAD Aviation fleet. Investors will also be listening for updates on the 2027 kidney trial timeline and progress in European expansion efforts to justify the current valuation.